SGK1 and osteoarthritis: Treatment with each lead compound at a concentration of 2 μM reduced the staining intensity of collagen type X. Collectively, 16y, 16z, and 17a controlled osteoarthritis pathology, which was well-correlated with the SGK1 inhibitory activities of the lead compounds.